Clinical Trial Update: BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for BRiTE, a bispecific T cell engager, being studied in glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BRiTE (bispecific T cell engager)

Snippet

Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Conditions: Newly Diagnosed Glioblastoma, Recurrent Glioblastoma | Phase 1 | Status: NOT_YET_RECRUITING